Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. - Wikidata - awgldk - TriplyDB

Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques.

Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques.

http://www.wikidata.org/entity/Q34909445

about

The alpha-gal story: lessons learned from connecting the dots.Glycan analysis of therapeutic glycoproteins Delayed Anaphylaxis Involving IgE to Galactose-alpha-1,3-galactose.Anaphylaxis to the carbohydrate side chain alpha-gal Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation Investigating Therapeutic Protein Structure with Diethylpyrocarbonate Labeling and Mass Spectrometry.Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches A new tool for monoclonal antibody analysis: application of IdeS proteolysis in IgG domain-specific characterization.Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes EndoS and EndoS2 hydrolyze Fc-glycans on therapeutic antibodies with different glycoform selectivity and can be used for rapid quantification of high-mannose glycans Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS.The Impact II, a Very High-Resolution Quadrupole Time-of-Flight Instrument (QTOF) for Deep Shotgun Proteomics.Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma Processing of complex N-glycans in IgG Fc-region is affected by core fucosylation Full validation of therapeutic antibody sequences by middle-up mass measurements and middle-down protein sequencing.Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.Consequences of glycan truncation on Fc structural integrity.Using glyco-engineering to produce therapeutic proteins.Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.The use of proteases complementary to trypsin to probe isoforms and modifications.Bacterial production and structure-functional validation of a recombinant antigen-binding fragment (Fab) of an anti-cancer therapeutic antibody targeting epidermal growth factor receptor.Rapid and improved characterization of therapeutic antibodies and antibody related products using IdeS digestion and subunit analysis.Top-down analysis of immunoglobulin G isotypes 1 and 2 with electron transfer dissociation on a high-field Orbitrap mass spectrometer.Subunit mass analysis for monitoring antibody oxidation.Alpha-gal is a possible target of IgE-mediated reactivity to antivenom.Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.Advanced analyses of kinetic stabilities of iggs modified by mutations and glycosylation Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion.Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.Meat allergy associated with galactosyl-α-(1,3)-galactose (α-Gal)-Closing diagnostic gaps by anti-α-Gal IgE immune profiling.Glycan and Peptide IgE Epitopes of the TNF-alpha Blockers Infliximab and Adalimumab - Precision Diagnostics by Cross-Reactivity Immune Profiling of Patient Sera.Parsimonious Charge Deconvolution for Native Mass Spectrometry.Study and ICH validation of a reverse-phase liquid chromatographic method for the quantification of the intact monoclonal antibody cetuximab.Immunoprecipitation middle-up LC-MS for in vivo drug-to-antibody ratio determination for antibody-drug conjugates.Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.Combination of SDS-PAGE and intact mass analysis for rapid determination of heterogeneities in monoclonal antibody therapeutics.9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.

P2860

Q27023451-BE4B678D-FEA8-4BD9-BB59-3025D3B3923E Q28082842-F0DAEA9D-E447-458F-8B55-B7DACFBADA7C Q30279084-02410BCF-8445-4259-B63E-D425C76F430D Q30300243-B85D4082-D611-47ED-B82C-F8704028676D Q30360964-B5ED4255-24D7-41CB-A1DA-5A637CB87FD8 Q30379478-9FD437B8-211E-471A-A363-304198267606 Q33641917-4CD1F544-C6C7-4A78-9D5C-52412F52619E Q34223967-F6EE2D1D-D97D-46FE-8694-77CE2925EDA6 Q34468348-2EB38933-EAD8-4AD3-B999-3ADA5677960E Q35686671-06F0FC9B-8C9D-4718-93A5-5A109B181E56 Q35975965-40CCFE93-E042-4255-BE95-4052517B3994 Q36103872-858A1BF4-BD4E-4FC4-A2F9-349D3A377D76 Q36155208-5BC13FEA-C6A1-4B51-BFEC-5461AA19F6A3 Q36211489-2929AD06-A38C-4694-96BA-0701128FBABE Q37138423-D95945BD-8225-440A-8511-BFDBC6C41A4B Q37329842-CC9281D0-F9F6-4745-A288-45D0FD3DDA4C Q38309192-3BFD243C-5092-4D9A-B42D-08E28F71A223 Q38547311-ED3811E2-2442-4854-BF09-A2CCAE21590D Q38665164-51A76191-BF6C-4223-B329-4BBD1216A27D Q38668408-EE1C2F85-89A8-4A41-8FA6-493DF4F9A5B3 Q38755075-F0A15877-502B-4E25-8B73-7FEFEAD86779 Q38828582-FC8E6CA7-76C8-4C7C-B694-655C8D4A4885 Q38938858-7CD4D4E8-14A7-4E86-9AE5-A0419B368E5E Q39010405-2D2A7D6F-31C9-42AD-B7C0-5E099657742C Q40488832-8E37893E-C3B7-4143-8CA6-91678E2A04C9 Q41177029-16327843-0CB1-42C7-BA4B-1C050E047E67 Q41366211-5E899208-569C-471C-BF63-F7819B4FF8BD Q41718653-A365A143-98DE-4018-941E-4F00175DE786 Q41966465-06A920C2-5E66-460E-ABA5-6E093E50FA4E Q42846272-E40C17C7-5595-4987-9D91-792775BD821D Q45062518-039CE757-02D1-4B59-95C5-C3E930C18B6E Q45074275-EAFA39E5-BC70-4E7F-9961-4D667C4B9832 Q47555561-73A7EDD8-8BA4-490E-B690-5AFC6D76A796 Q48504497-33089670-1A51-4F14-985A-796A3196E124 Q50088579-10260CDC-73F6-452A-A2E9-4138E2439222 Q50098437-16A3005B-8E03-4091-B379-B5E983FF725D Q50860928-9B2E9F64-6331-474C-9034-EAABED11D0BC Q51238255-C5917016-F74A-4F50-8E81-FB9F062F8A01

P2860

Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques.

http://www.wikidata.org/entity/Q34909445

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Correct primary structure asse ...... mass spectrometry techniques.

@ast

Correct primary structure asse ...... mass spectrometry techniques.

@en

Correct primary structure asse ...... mass spectrometry techniques.

@nl

type

label

Correct primary structure asse ...... mass spectrometry techniques.

@ast

Correct primary structure asse ...... mass spectrometry techniques.

@en

Correct primary structure asse ...... mass spectrometry techniques.

@nl

prefLabel

Correct primary structure asse ...... mass spectrometry techniques.

@ast

Correct primary structure asse ...... mass spectrometry techniques.

@en

Correct primary structure asse ...... mass spectrometry techniques.

@nl

P1433

Q34909445-45D10F89-3B76-4233-AD5A-32961497FE6A

P1476

Q34909445-73B6BF79-AC9C-44BF-972B-7061761AA2D1

P2093

Q34909445-4B922D34-AC03-460B-83F6-331737BE3935

Q34909445-59BC6423-374A-42A4-A66B-56E832D8831B

Q34909445-6A7BEAB7-DEE7-4C5A-9EF9-6147DEC72495

Q34909445-7633B592-AB4B-4F17-8565-1C3BB8A75954

Q34909445-B1D45EF0-586F-44BD-8578-A7461A460D4F

Q34909445-BEE50B45-ECA2-4BC8-A29A-5DB35DAD3E90

Q34909445-DB89D284-5279-47B3-AA17-94A553CE0D72

Q34909445-F9CC0099-3773-4561-A2D6-061E0EBDD083

P2860

Q34909445-0000C58B-DF44-4AF4-908A-3A63101E7946

Q34909445-0A2EB8F2-18FD-4665-88B0-1DC8BCC1E1E9

Q34909445-247B78A6-BA9C-4C97-B1C5-D78EDFB04D52

Q34909445-2B83D4CF-5076-49AA-8AC4-08FF9C06CC90

Q34909445-3612FF6D-DC2A-4198-A91C-10BAFE813809

Q34909445-366273F9-D31C-4296-B35E-E9F6C75AD904

Q34909445-5B38C523-8B87-4D05-A4C7-5DC26069041E

Q34909445-66F37F8C-177F-495C-A1C1-DF09659BFDED

Q34909445-73B48E05-0746-4836-9AC8-17C51841DF77

Q34909445-7622CB9C-2D35-4B80-B51A-BA4EDEB25F50

P304

Q34909445-2F357583-63B7-4E7D-B809-05042A7B2A84

P31

Q34909445-0865DFC1-60C1-4BBF-8501-883963325377

P356

Q34909445-5D3EA991-C584-4523-AD9A-AC0A0F2C7CCF

P433

Q34909445-A4FD2DC3-2E45-42FB-809B-0C47D5ACF4B8

P478

Q34909445-EEBEFB72-9605-4292-B9E7-A3D545E7796C

P50

Q34909445-32B6E7B1-BFB0-4D29-BFC6-3130128FC10C

Q34909445-374EBC25-9131-4052-AFB4-4A9057B5C438

P577

Q34909445-BAA2337F-A59A-422A-9633-E8FB9D93ABDE

P5875

Q34909445-FB513C2C-8756-4AC4-B8F9-65D4F699FFA2

P698

Q34909445-2505F3BD-0564-422B-9963-66EA5CD8A100

P921

Q34909445-61172F8A-62CB-41E7-AB90-8727CBF90768

Q34909445-62B64C5A-E918-459B-A395-E8273542D7BD

P932

Q34909445-80B28F86-D1FB-429D-B980-38AF7E422D64

P356

P1433

Monoclonal Antibodies

P1476

Correct primary structure asse ...... I mass spectrometry techniques

@en

P2093

Alain Beck

http://www.w3.org/2001/XMLSchema#string

Anja Resemann

http://www.w3.org/2001/XMLSchema#string

Carsten Baessmann

http://www.w3.org/2001/XMLSchema#string

Catherine Evans

http://www.w3.org/2001/XMLSchema#string

Elsa Wagner-Rousset

http://www.w3.org/2001/XMLSchema#string

Laura Main

http://www.w3.org/2001/XMLSchema#string

Waltraud Evers

http://www.w3.org/2001/XMLSchema#string

Wolfgang Jabs

http://www.w3.org/2001/XMLSchema#string

P2860

GlycomeDB--a unified database for carbohydrate structures

Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats

Protein sequence information by matrix-assisted laser desorption/ionization in-source decay mass spectrometry

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

Glycoproteomics based on tandem mass spectrometry of glycopeptides.

T3-sequencing: targeted characterization of the N- and C-termini of undigested proteins by mass spectrometry.

Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequentia

Rational selection of the optimum MALDI matrix for top-down proteomics by in-source decay.

Mass spectrometry for structural characterization of therapeutic antibodies.

Top-down de Novo protein sequencing of a 13.6 kDa camelid single heavy chain antibody by matrix-assisted laser desorption ionization-time-of-flight/time-of-flight mass spectrometry.

P304

699-710

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.25423

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255706201

http://www.w3.org/2001/XMLSchema#string

P698

23924801

http://www.w3.org/2001/XMLSchema#string

P921

matrix-assisted laser desorption/ionization

P932

3851223

http://www.w3.org/2001/XMLSchema#string